Certolizumab and Anti-Certolizumab Antibody, DoseASSURE CTZ

Clinical Use

Use

Certolizumab and Anti-Certolizumab Antibody testing is crucial for managing and monitoring patients undergoing treatment with certolizumab pegol, a biologic TNF inhibitor. This test helps in determining the drug and anti-drug antibody levels in the serum, offering insights into the drug's efficacy and immunogenic response. By analyzing these components, clinicians can assess whether the patient is achieving the desired therapeutic levels or if alterations in drug dosing or therapy adjustments are necessary due to suboptimal drug levels or the presence of anti-drug antibodies.

Special Instructions

Not provided.

Limitations

The test measurements are influenced by patient-specific factors such as concurrent medications, disease state, and individual therapeutic goals. Specimen collection timing, especially trough concentrations, is critical for interpreting drug levels based on standard clinical ranges. Moreover, optimal certolizumab concentrations may not always correlate with clinical efficacy due to factors like the presence of anti-drug antibodies or mechanistic failures. These limitations necessitate that test results be considered alongside clinical evaluations and other diagnostic measures.

Test Details

New York Approved